Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 7% – Time to Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s share price dropped 7% during mid-day trading on Monday . The stock traded as low as $18.34 and last traded at $18.58. Approximately 72,167 shares changed hands during trading, a decline of 70% from the average daily volume of 241,564 shares. The stock had previously closed at $19.99.

Wall Street Analyst Weigh In

DNTH has been the subject of a number of research analyst reports. Guggenheim reaffirmed a “buy” rating and set a $84.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. TD Cowen started coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating for the company. Wedbush reissued an “outperform” rating and set a $36.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $54.33.

Dianthus Therapeutics Trading Down 8.2 %

The company has a market capitalization of $589.78 million, a P/E ratio of -7.35 and a beta of 1.82. The stock’s fifty day moving average is $21.91 and its 200 day moving average is $24.24.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The business had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. On average, analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Several hedge funds have recently made changes to their positions in DNTH. TCG Crossover Management LLC purchased a new position in Dianthus Therapeutics during the fourth quarter valued at $32,735,000. Braidwell LP lifted its position in Dianthus Therapeutics by 144.4% during the 4th quarter. Braidwell LP now owns 1,206,589 shares of the company’s stock valued at $26,304,000 after acquiring an additional 712,902 shares during the period. Vestal Point Capital LP boosted its stake in Dianthus Therapeutics by 172.2% during the fourth quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company’s stock worth $23,435,000 after acquiring an additional 680,000 shares in the last quarter. State Street Corp grew its holdings in Dianthus Therapeutics by 101.4% in the third quarter. State Street Corp now owns 821,131 shares of the company’s stock worth $22,483,000 after purchasing an additional 413,425 shares during the period. Finally, Octagon Capital Advisors LP increased its stake in shares of Dianthus Therapeutics by 20.8% during the fourth quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company’s stock valued at $46,002,000 after purchasing an additional 363,500 shares in the last quarter. 47.53% of the stock is currently owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.